Title:
Evaluating Adherence to Eye Care Recommendations Amongst Patients Receiving Antibody Drug Conjugates for Gynecologic Malignancies
Authors:
Ram Patel, PharmD
Kelli McCrum, PharmD
Michael Saxon, PharmD, BCPS
Objectives:
- Primary Objective: Assess compliance with prescribed eye drops.
- Secondary Objectives:
- Identify correlations between adherence and ocular toxicity.
- Evaluate the effectiveness of patient education in mitigating adverse effects.
Self Assessment Questions:
How does adherence to eye care measures correlate with the incidence of ocular toxicity? What factors influence patient adherence to prophylactic eye drop regimens?
Background:
Antibody-drug conjugates (ADCs) such as mirvetuximab soravtansine and tisotumab vedotin have demonstrated efficacy in treating gynecologic malignancies but are associated with ocular toxicity, necessitating preventive eye care measures. This study aims to evaluate adherence to prophylactic eye drop regimens among patients receiving these therapies. The primary objective is to assess compliance with prescribed eye drops, while secondary objectives include identifying correlations between adherence and ocular toxicity and evaluating the effectiveness of patient education in mitigating adverse effects.
Methods:
A cross-sectional, prospective study was conducted to assess adherence to prophylactic eye drops in patients receiving mirvetuximab soravtansine or tisotumab vedotin. Eligible patients completed a structured questionnaire evaluating adherence to steroid, lubricating, and vasoconstrictor eye drops (for tisotumab patients only). Inclusion criteria consisted of patients actively receiving ADC therapy, those prescribed prophylactic eye drops, and English-speaking patients. Data collection included duration of eye drop prophylaxis, frequency, dosage, and adherence, measured via a Likert scale. Patients also assessed their understanding of eye care importance and reported any ocular symptoms.
Results:
Preliminary data from four patient encounters indicate adherence to eye drop regimens at 100%, adequate understanding of their regimen at 100%, and minimal ocular toxicities. Reported toxicities include dry eyes being reported in 100% of patient encounters, blurry vision reported in 25%, and sensitivity to light reported in 25%. Our current hypothesis suggests that higher rates of adherence correlates with a lower incidence of ocular toxicity. With the limited number of patient encounters thus far demonstrating adherence and understanding of their regimens, more data is needed to draw any further conclusions or correlations. This study also examines patient-reported barriers to adherence, such as difficulty remembering doses, perceived ineffectiveness, or discomfort caused by the drops.
Conclusion:
This study provides valuable insights into adherence patterns, ocular toxicity risks, and the effectiveness of patient education in mitigating adverse events. Identifying key adherence barriers and their impact on toxicity rates may inform strategies to improve compliance and patient outcomes. Enhanced adherence to prophylactic eye care measures could reduce treatment-related complications, improving tolerability and quality of life for patients receiving ADC therapy. Ultimately, these findings may contribute to the development of standardized adherence protocols to optimize patient care and minimize ocular toxicity in clinical practice.
